🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Medical.watch - See what physicians are saying about your brand on social media The weekly newsletter on CRC is now available for subscribers ⁦Medical.watch⁩ ⁦Kate Sears⁩ my.medical.watch

Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST) 🔍 Key Highlights: ✅ctDNA dynamics can predict treatment response earlier than imaging. 📊 ✅Proposed LB-RECIST criteria aim to standardize ctDNA-based response assessment. 📝 ✅A step forward for

Historic milestone🎯🥇

Historic milestone 🎯🥇 for first-line #mCRC treatment of #BRAF V600E mut patients based on #BREAKWATER study FDA grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer OncoAlert #GIonc fda.gov/drugs/resource…

🙏🏻 Grateful to Medical.watch and Kate Sears to promote the results of IMPROVE trial on Journal of Clinical Oncology ascopubs.org/doi/pdf/10.120… in the weekly newsletter! To be always updated on the most recent news and trials, you can subscribe at my.medical.watch/signup

Dr Amol Akhade Want the top posts, podcasts and more? Subscribe to our weekly newsletter and join 2,400 clinicians. Sign up free 👇👇👇

📢Very useful suggestions from Medical.watch Kate Sears directly forwarded to your📁📬email. You can subscribe to get a monthly update on phase 3 interventional clinical trials recruiting near you on your field of interest. Congrats and thanks for this project!

Alfonso De Stefano Get clinical trials near you, congress highlights and more 🙂

Happy New Year to everyone!

Interesting review on advances in targeting 🎯KRAS in #mCRC OncoAlert OncoDaily GI Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer by Dustin Deming on Journal of the @NCCN jnccn.org/view/journals/…

Thanks OncoDaily to share our results from #IMPROVE trial Continuous(C) vs Intermittent(I) ChT in #mCRC Journal of Clinical Oncology ascopubs.org/doi/pdf/10.120… ✅Endpoint met 👉mPFSot 11.2(C)vs17.5months(I) 👉NO detrimental effect on OS 👉DCR 94.2%(C)vs91%(I) 👉⬇️skin tox oncodaily.com/blog/panitumum…

Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC oncodaily.com/url/225453 Dr Akhil Santhosh Alfonso De Stefano #Cancer #GIOnc #Crcsm #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

Long awaited practice-changing results from ph 3 CM8HW now out in The Lancet. Nivo/ipi sign better than nivo mono in dMMR mCRC Sara Lonardi Bristol Myers Squibb #GI25 thelancet.com/journals/lance…

An analysis of published studies suggests that a longer duration of immune checkpoint inhibitor therapy is associated with a higher incidence of complete response among patients with mismatch repair–deficient cancers. Full correspondence: nej.md/3EXiEpe

Many thanks to Digestive Cancers Europe to share our ongoing phase III #IMPROVE-2 trial, highlighting the possible advantages of #intermittent therapy with FOLFIRI-Panitumumab in RAS BRAF wild-type #mCRC patients digestivecancers.eu/improve-2-tria…

Intermittent or Continuous Panitumumab + FOLFIRI for 1st line RAS and BRAF WT mCRC Journal of Clinical Oncology doi.org/10.1200/JCO.24… 🔎IMPROVE Trial 👉ORR 68.1 vs 61.2%, 👉mPFS: 11.2 vs 17.5 mo 👉mOS: 36.3 vs 35.1 mo 🧐Intermittend Tx feasible, less tox ESMO - Eur. Oncology

14) IMPROVE Trial "Intermittent FOLFIRI plus PANITUMUMAB after the induction phase was feasible, and the primary end point was met with reduced toxicity while allowing patients more time off treatment." ascopubs.org/doi/full/10.12…

📢 Exciting update in the field of liquid biopsy! A new editorial highlights the essential role of the International Society of Liquid Biopsy (ISLB) in establishing quality framework for LB clinical implementation. 🧬🩸 This document underscores the importance of standardized

Pleased to share our latest manuscript published in ESMO Open 📢 Luca Boscolo Bielo Giulia Martini erika martinelli Massimo Di Maio Chiara Cremolini Stefania Napolitano Tiziana Latiano Alfonso De Stefano G Curigliano MD PhD G Curigliano MD PhD esmoopen.com/article/S2059-…

2025 ISLB Annual Congress, will take place in Orlando, Florida, November 1-3, 2025. This is an extraordinary gathering of scientists, clinicians, industry leaders, and innovators, all united by a shared passion for advancing liquid biopsy 2025.islb.info